drugset / Trial / NCT04436458

Niclosamide In Moderate COVID-19

NCT04436458

Phase 2 Withdrawn Entero Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.

Timeline

Start
2022-01-20
Primary completion
2022-01-20
Completion
2022-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Niclosamide Unknown Oral

Indications